Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2335)	3/25/2008 12:00:21 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MSHL is up 13.04% on light volume of 21,877 which is already above its ADV.<g> bigcharts.marketwatch.com It presented an abstarct at the AACR titled "Triphendiol (NV-196) induces apoptosis and sensitizes pancreatic cancer cells to gemcitabine." The drug was recently granted orphan drug status by the FDA for malignant melanoma & for the treatment of cholangiocarcinoma. The stock needs to close above $3.08 in order to get off the DT coming from its Nov 12 spike to $3.98 bigcharts.marketwatch.com The stock trades around 11xBV, it has small LTD & the short ratio, which increased recently, is around 30x its ADV.(With some good news, it could have another spike on short covering.<g>) The all time H on the Jan & Feb 2004 double top was $13.10 bigcharts.marketwatch.com Bernard